239 related articles for article (PubMed ID: 37524698)
1. circRNA-SFMBT2 orchestrates ERα activation to drive tamoxifen resistance in breast cancer cells.
Li Z; Li Y; Han D; Wang X; Li C; Chen T; Li W; Liang Y; Luo D; Chen B; Wang L; Zhao W; Yang Q
Cell Death Dis; 2023 Jul; 14(7):482. PubMed ID: 37524698
[TBL] [Abstract][Full Text] [Related]
2. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
Zhu J; Li X; Su P; Xue M; Zang Y; Ding Y
Oncogene; 2020 Oct; 39(44):6776-6788. PubMed ID: 32973333
[TBL] [Abstract][Full Text] [Related]
3. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
4. CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.
Yi J; Wang L; Hu GS; Zhang YY; Du J; Ding JC; Ji X; Shen HF; Huang HH; Ye F; Liu W
EMBO J; 2023 May; 42(10):e112408. PubMed ID: 37009655
[TBL] [Abstract][Full Text] [Related]
5. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
6. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
7. miR-489 Confines Uncontrolled Estrogen Signaling through a Negative Feedback Mechanism and Regulates Tamoxifen Resistance in Breast Cancer.
Soni M; Saatci O; Gupta G; Patel Y; Keerthi Raja MR; Li J; Liu X; Xu P; Wang H; Fan D; Sahin O; Chen H
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897675
[TBL] [Abstract][Full Text] [Related]
8. VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H; Urruticoechea A; Halonen P; Kiyotani K; Mushiroda T; Barril X; Serra-Musach J; Islam A; Caizzi L; Di Croce L; Nevedomskaya E; Zwart W; Bostner J; Karlsson E; Pérez Tenorio G; Fornander T; Sgroi DC; Garcia-Mata R; Jansen MP; García N; Bonifaci N; Climent F; Soler MT; Rodríguez-Vida A; Gil M; Brunet J; Martrat G; Gómez-Baldó L; Extremera AI; Figueras A; Balart J; Clarke R; Burnstein KL; Carlson KE; Katzenellenbogen JA; Vizoso M; Esteller M; Villanueva A; Rodríguez-Peña AB; Bustelo XR; Nakamura Y; Zembutsu H; Stål O; Beijersbergen RL; Pujana MA
Breast Cancer Res; 2014 May; 16(3):R53. PubMed ID: 24886537
[TBL] [Abstract][Full Text] [Related]
9. FOXC1 is involved in ERα silencing by counteracting GATA3 binding and is implicated in endocrine resistance.
Yu-Rice Y; Jin Y; Han B; Qu Y; Johnson J; Watanabe T; Cheng L; Deng N; Tanaka H; Gao B; Liu Z; Sun Z; Bose S; Giuliano AE; Cui X
Oncogene; 2016 Oct; 35(41):5400-5411. PubMed ID: 27041579
[TBL] [Abstract][Full Text] [Related]
10. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα.
Yang P; Yang X; Wang D; Yang H; Li Z; Zhang C; Zhang S; Zhu J; Li X; Su P; Zhuang T
Oncogene; 2024 Jan; 43(4):248-264. PubMed ID: 38017133
[TBL] [Abstract][Full Text] [Related]
11. Reprogramming of the ERRα and ERα target gene landscape triggers tamoxifen resistance in breast cancer.
Thewes V; Simon R; Schroeter P; Schlotter M; Anzeneder T; Büttner R; Benes V; Sauter G; Burwinkel B; Nicholson RI; Sinn HP; Schneeweiss A; Deuschle U; Zapatka M; Heck S; Lichter P
Cancer Res; 2015 Feb; 75(4):720-31. PubMed ID: 25643697
[TBL] [Abstract][Full Text] [Related]
12. HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance.
Jin K; Park S; Teo WW; Korangath P; Cho SS; Yoshida T; Győrffy B; Goswami CP; Nakshatri H; Cruz LA; Zhou W; Ji H; Su Y; Ekram M; Wu Z; Zhu T; Polyak K; Sukumar S
Cancer Discov; 2015 Sep; 5(9):944-59. PubMed ID: 26180042
[TBL] [Abstract][Full Text] [Related]
13. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
14. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
15. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
[TBL] [Abstract][Full Text] [Related]
16. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
Wen J; Li R; Lu Y; Shupnik MA
Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
[TBL] [Abstract][Full Text] [Related]
17. UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.
Chen XS; Wang KS; Guo W; Li LY; Yu P; Sun XY; Wang HY; Guan YD; Tao YG; Ding BN; Yin MZ; Ren XC; Zhang Y; Chen CS; Ye YC; Yang JM; Cheng Y
Theranostics; 2020; 10(4):1833-1848. PubMed ID: 32042339
[No Abstract] [Full Text] [Related]
18. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer.
Gong C; Tsoi H; Mok KC; Cheung J; Man EPS; Fujino K; Wong A; Lam EWF; Khoo US
Oncogene; 2020 Apr; 39(15):3206-3217. PubMed ID: 32066877
[TBL] [Abstract][Full Text] [Related]
20. An epigenomic approach to therapy for tamoxifen-resistant breast cancer.
Feng Q; Zhang Z; Shea MJ; Creighton CJ; Coarfa C; Hilsenbeck SG; Lanz R; He B; Wang L; Fu X; Nardone A; Song Y; Bradner J; Mitsiades N; Mitsiades CS; Osborne CK; Schiff R; O'Malley BW
Cell Res; 2014 Jul; 24(7):809-19. PubMed ID: 24874954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
